Functional inhibition of PI3K by the βGBP molecule suppresses Ras-MAPK signalling to block cell proliferation

Oncogene

Volumn 26, Issue 55, 2007, Pages 7709-7714

  Wells, V ^a   Downward, J ^b   Mallucci, L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

galactoside binding protein; GBP; MAPK; PI3K; Ras

Indexed keywords

GALAPTIN; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN P110; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GALECTIN 1; HUMANS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 36849006081     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210580     Document Type: Article

References (33)

1. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A. (1984). Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumours. Cancer Genet Cytogenet 12: 21-25.
2. Baldini A, Gress T, Patel K, Muresu R, Chiariotti L, Williamson P et al. (1993). Mapping on human and mouse chromosomes of the gene for the β galactoside binding protein, an autocrine negative growth factor. Genomics 15: 216-218.
3. Blaser C, Kaufman M, Muller C, Zimmermann C, Wells V, Mallucci L et al. (1998). β-galactoside binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 28: 2311-2319.
4. Bridge JA, Borek DA, Neff JR, Huntrakoon M. (1990). Chromosomal abnormalities in clear cell carcinoma. Implications for histogenesis. Am J Clin Pathol 93: 26-31.
5. Cantley LC. (2002). Phosphoinositide-3-kinase pathway. Science 296: 1655-1657.
6. Chiariotti L, Wells V, Bruni CB, Mallucci L. (1991). Structure and expression of the negative growth factor mouse β-galactoside binding protein gene. Biochim Biophys Acta 1089: 54-60.
7. Downward J. (2003). Targeting Ras signaling pathways in cancer therapy. Nat Rev 3: 11-22.
8. Finney RE, Robbins SM, Bishop JM. (1993). Association of pRas and pRaf-1 in a complex correlates with activation of signal transduction pathways. Curr Biol 3: 805-812.
9. Garcia Z, Kumar A, Marques M, Cortes I, Carrera AC. (2006). Phosphoinositide-3-kinase controls early and late events in mammalian cell division. EMBO J 25: 655-661.
10. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ. (1996). Phosphatidylinositol 3-kinase is an early intermediate in the Gβγ-mediated mitogen-activated protein kinase signalling pathway. J Biol Chem 271: 12133-12136.
11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Links exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
12. Hirabayashi J, Akayi H, Soma G, Kasai K. (1989). Production and purification of a recombinant human 14 kDa β-galactoside-binding lectin. FEBS Lett 250: 161-165.
13. Kharitonevkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. (1997). A family of proteins that inhibits signalling through tyrosine kinase receptors. Nature 386: 181-186.
14. ras. Proc Natl Acad Sci USA 91: 12706-12710.
15. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. (1998). Gβγ stimulates phosphatidylinositol 3-kinase by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 273: 7024-7029.
16. Mallucci L, Wells V, Danikas A, Davies D. (2003). Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine (βGBP). Biochem Pharmacol 66: 1563-1569.
17. Mitin N, Rossmann KL, Der CJ. (2005). Signaling interplay in Ras superfamily function. Curr Biol 15: R563-R574.
18. Panayotou G, Bax B, Gout I, Federwisch M, Wroblowski B, Dhand R et al. (1992). Interaction of the p85 subunit of PI3-kinase and the N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes. EMBO J 11: 4261-4272.
19. Powis G, Boujouklian R, Berggren MM, Gallegos A, Abraham R., Ashendel C. (1994). Wortmannin, a potent selective inhibitor of phosphatidylinositol-3- kinase. Cancer Res 59: 2419-2423.
20. Ravatn R, Wells V, Nelson L, Vettori D, Mallucci L, Chin KV. (2005). Circumventing multidrug resistance in cancer by β-galactoside binding protein, an antiproliferative cytokine. Cancer Res 65: 1631-1634.
21. Rey JA, Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL et al. (1993). Abnormalities of chromosome 22 in human brain tumors determined by combined cytogenetic and molecular genetic approaches. Cancer Genet Cytogenet 66: 1-10.
22. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry M et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532.
23. Schonwasser OC, Marais RM, Marshall CJ, Parker P. (1998). Activation of mitogen-activated protein kinase/extracellular signal regulated kinase pathway by conventional, novel and atypical protein kinase C isotypes. Mol Cell Biol 18: 790-798.
24. Suire S, Coadwell J, Ferguson T, Davidson K, Hawkins P, Stephens L. (2005). p84, a new βγ-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110γ. Curr Biol 15: 566-570.
25. Turc-Carel C, Dal Cin P, Rao U, Karakousis C, Sandberg AA. (1998). Recurrent breakpoints at 9q31 and 22q12.2 in extraskeletal myzoid chondrosarcoma. Cancer Genet Cytogenet 30: 145-150.
26. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll P. (2001). Synthesis and function of 3- phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602.
27. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biol Sci 22: 267-272.
28. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev 2: 489-501.
29. Vlahos CJ, Matter WT, Hui KY, Brown F. (1994). A specific inhibitor of phosphatidylinositol-3-kinase,2-(morpholinyl)-8-4H-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
30. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. (2000). Structural determination of phosphoinositol-3-kinase by wortmannin and LY294002, quercetin, myricetin and staurosporine. Mol Cell 6: 909-919.
31. Wells V, Mallucci L. (1991). Identification of an autocrine negative growth factor: mouse-β-galactoside binding protein is a cytostatic factor and cell growth regulator. Cell 64: 91-97.
32. Wells V, Mallucci L. (1992). Molecular expression of the negative growth factor murine-β-galactoside binding protein (mGBP). Biochim Biophys Acta 1121: 239-244.
33. Wennstrom S, Downward J. (1999). Role of phosphoinositide 3-kinase in activation of Ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279-4288.